<DOC>
	<DOCNO>NCT01936974</DOCNO>
	<brief_summary>To evaluate progression-free survival two chemotherapy regimens platinum-resistant/refractory ovarian peritoneal carcinoma</brief_summary>
	<brief_title>( PGA ) Platinum-resistant/Refractory , Paclitaxel-Pretreated Recurrent Ovarian Peritoneal Carcinoma</brief_title>
	<detailed_description>This study evaluate progression-free survival ( PFS ) regimen gemcitabine bevacizumab without platinum agent platinum-resistant/refractory ovarian peritoneal carcinoma</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Fallopian Tube Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>1 . Patients ≥ 18 year age histologically confirm , recurrent epithelial ovarian , fallopian tube , primary peritoneal cancer 2 . Disease progression within 6 month previous platinumbased chemotherapy include follow 4 category : 1 . Primary platinumrefractory : Previously untreated patient achieve least partial response platinumbased chemotherapy 2 . Primary platinumresistant : Previously untreated patient achieve least partial response platinumbased chemotherapy experience relapse within period 6 month conclusion 3 . Secondary platinumrefractory : Previously treat patient relapse 6 month conclusion chemotherapy , fail achieve least partial response 4 . Secondary platinumresistant : Previously treat patient relapse 6 month conclusion chemotherapy , achieve least partial response platinumbased therapy 2ndline therapy , experience relapse within 6 month 3 . Eastern Cooperative Oncology Group ( ECOG ) performance status score ≤ 2 life expectancy &gt; 3 month . 4 . Absolute neutrophil count &gt; 1500 mm^3 , platelet count ≥ 100×10^9 L , hemoglobin ≥ 8.5 g/dL 5 . Serum creatinine ≤1.5 time upper limit normal range , total bilirubin ≤ 2 mg/dL , AST/ALT ≤ 5 time upper limit normal range 6 . No remain grade 2 high toxicity prior cancer therapy unless judge clinically insignificant Principal Investigator 7 . At least three ( 3 ) week prior chemotherapy 1 . Inadequate renal function calculate creatinine clearance le 51 mL/min 2 . Uncontrolled cardiac disease , congestive heart failure , angina , hypertension 3 . Myocardial infarction unstable angina within 2 month treatment 4 . Known human immunodeficiency virus ( HIV ) infection chronic active Hepatitis B C ( patient NOT require test presence virus prior therapy protocol ) 5 . Thrombotic embolic event cerebrovascular accident include transient ischemic attack , pulmonary embolism within past 6 month 6 . Bleeding diathesis significant coagulopathy 7 . Pulmonary hemorrhage/bleeding event ≥ CTCAE Grade 2 within 4 week first dose study drug 8 . Any hemorrhage/bleeding event ≥ CTCAE Grade 3 within 4 week first dose study drug 9 . History fistula , GI perforation , intrabdominal abscess 10 . Serious nonhealing wound , ulcer , bone fracture 11. clinical sign symptom GI obstruction and/or requirement parenteral hydration nutrition 12 . Known CNS disease except treated brain metastasis 13 . Known platinum drug allergy 14 . Prior treatment Platinum + Gemcitabine + Avastin , Gemcitabine + Avastin Gemcitabine alone 15 . Prior treatment three ( 3 ) line chemotherapy include adjuvant chemotherapy 16 . Major surgery , open biopsy significant traumatic injury within 4 week first study drug 17 . Inability complete inform consent process adhere protocol treatment plan followup requirement 18 . Concurrent severe illness active infection , psychiatric illness/social situation would limit safety compliance study requirement</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2015</verification_date>
</DOC>